» Articles » PMID: 38256139

Graphene Oxide Nanoparticles and Organoids: A Prospective Advanced Model for Pancreatic Cancer Research

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Jan 23
PMID 38256139
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer, notorious for its grim 10% five-year survival rate, poses significant clinical challenges, largely due to late-stage diagnosis and limited therapeutic options. This review delves into the generation of organoids, including those derived from resected tissues, biopsies, pluripotent stem cells, and adult stem cells, as well as the advancements in 3D printing. It explores the complexities of the tumor microenvironment, emphasizing culture media, the integration of non-neoplastic cells, and angiogenesis. Additionally, the review examines the multifaceted properties of graphene oxide (GO), such as its mechanical, thermal, electrical, chemical, and optical attributes, and their implications in cancer diagnostics and therapeutics. GO's unique properties facilitate its interaction with tumors, allowing targeted drug delivery and enhanced imaging for early detection and treatment. The integration of GO with 3D cultured organoid systems, particularly in pancreatic cancer research, is critically analyzed, highlighting current limitations and future potential. This innovative approach has the promise to transform personalized medicine, improve drug screening efficiency, and aid biomarker discovery in this aggressive disease. Through this review, we offer a balanced perspective on the advancements and future prospects in pancreatic cancer research, harnessing the potential of organoids and GO.

Citing Articles

Surface Engineering of Magnetic Iron Oxide Nanoparticles for Breast Cancer Diagnostics and Drug Delivery.

Xie M, Meng F, Wang P, Diaz-Garcia A, Parkhats M, Santos-Oliveira R Int J Nanomedicine. 2024; 19:8437-8461.

PMID: 39170101 PMC: 11338174. DOI: 10.2147/IJN.S477652.


Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma.

Budka J, Debowski D, Mai S, Narajczyk M, Hac S, Rolka K Pharmaceutics. 2024; 16(2).

PMID: 38399336 PMC: 10892429. DOI: 10.3390/pharmaceutics16020283.

References
1.
Guo S, Song Z, Ji D, Reina G, Fauny J, Nishina Y . Combined Photothermal and Photodynamic Therapy for Cancer Treatment Using a Multifunctional Graphene Oxide. Pharmaceutics. 2022; 14(7). PMC: 9318106. DOI: 10.3390/pharmaceutics14071365. View

2.
Lee D, Su J, Kim H, Chang B, Papatsenko D, Zhao R . Modeling familial cancer with induced pluripotent stem cells. Cell. 2015; 161(2):240-54. PMC: 4397979. DOI: 10.1016/j.cell.2015.02.045. View

3.
Grilli F, Hassan E, Variola F, Zou S . Harnessing graphene oxide nanocarriers for siRNA delivery in a 3D spheroid model of lung cancer. Biomater Sci. 2023; 11(19):6635-6649. DOI: 10.1039/d3bm00732d. View

4.
Wang Y, Sun G, Gong Y, Zhang Y, Liang X, Yang L . Functionalized Folate-Modified Graphene Oxide/PEI siRNA Nanocomplexes for Targeted Ovarian Cancer Gene Therapy. Nanoscale Res Lett. 2020; 15(1):57. PMC: 7058751. DOI: 10.1186/s11671-020-3281-7. View

5.
Chen Z, Wei X, Dong S, Han F, He R, Zhou W . Challenges and Opportunities Associated With Platelets in Pancreatic Cancer. Front Oncol. 2022; 12:850485. PMC: 9039220. DOI: 10.3389/fonc.2022.850485. View